Opdivo (Nivolumab) Receives FDA Supplemental Approval for Efficacy

A supplemental application for the drug Opdivo (nivolumab) received approval from the U.S. Food and Drug Administration (FDA) on 2017-04-25. This approval was granted based on new efficacy data, indicating an expansion or modification of the drug's approved uses, which is a significant update for clinicians and patients.

Background

Nivolumab, known commercially as Opdivo, is a well-established therapeutic agent. This supplemental approval, sponsored by Bristol Myers Squibb, specifically pertains to its efficacy profile. Supplemental applications are a common regulatory mechanism used to update an already approved drug's label. These updates can include new indications, expanded patient populations, updated dosing regimens, or other changes based on new clinical data demonstrating benefit for an already approved drug.

What this means

The FDA's supplemental approval for Opdivo (nivolumab) on 2017-04-25, based on new efficacy data, signifies an important update to the drug's prescribing information. For clinicians, this means there is now an expanded scope for using nivolumab, potentially offering a new treatment option for a specific patient population or disease context not previously covered. While the precise details of the new indication or patient population are not specified in the provided source data, such approvals are typically granted after rigorous review of clinical trial data demonstrating a favorable benefit-risk profile for the new use. This update allows healthcare providers to consider nivolumab for additional therapeutic applications, potentially improving patient outcomes in the relevant disease area. Patient advocates and researchers will also note this as an expansion of treatment possibilities for Opdivo.

Source

This information was obtained from the U.S. Food and Drug Administration (FDA) through its official drug approvals database. The supplemental application, identified by the FDA as BLA 125554 S-31, received approval on 2017-04-25. Further details are accessible via the FDA's accessdata.fda.gov portal.